Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.61 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.61 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.61 |
| ▸ | GGH | Q92820 | 1/20 | 0.57 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.46 |
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162038 | 1.00 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| SCHEMBL31599178 | 1.00 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| SCHEMBL180085 | 1.00 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| Ammonia Solution, Strong SCHEMBL10700813 | 0.98 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| Hydrochloric Acid SCHEMBL27904743 | 0.98 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| Hydrochloric Acid SCHEMBL5321442 | 0.98 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| SCHEMBL10830382 | 0.98 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| SCHEMBL18575228 | 0.98 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| SCHEMBL28160359 | 0.98 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLAGGHANPEP | |
| SCHEMBL29973847 | 0.92 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGHANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1996 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20220162261-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2022-05-26 | — | — | US | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-20090215895-A1 | Therapeutic and carrier molecules | PEPLIN BIOLIPIDS PTY LTD (AU) | 2009-08-27 | — | — | US | claimed |
| EP-1718602-A4 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2007-12-12 | — | — | EP | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| EP-1718602-A1 | THERAPEUTIC AND CARRIER MOLECULES | Peplin Biolipids Pty Ltd. (AU) | 2006-11-08 | — | — | EP | claimed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | claimed |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-21 | — | — | US | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-04-23 | — | — | US | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0434979-A1 | Peptide derivatives useful as antagonists of bombesin and gastrin-releasing peptide | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| EP-0211223-A2 | Spherical grains of poly(alpha-amino acid)and production method thereof | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute (JP) | 1987-02-25 | — | — | EP | disclosed |
| US-3985617-A | IMMOBILIZATION OF BIOLOGICALLY ACTIVE PROTEINS WITH A POLYPEPTIDE AZIDE | AJINOMOTO CO., INC. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215895-A1 | Therapeutic and carrier molecules | PHKG1, PHKG2, DGKB | FOLH1 2178/4885NAALAD2 4393/4885RIMKLA 4048/4885 |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | FOLH1 1731/4885NAALAD2 4205/4885RIMKLA 1666/4885 |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | FOLH1 847/4885NAALAD2 2085/4885RIMKLA 4027/4885 |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | NONO, NGLY1, PTMS | FOLH1 1584/4885NAALAD2 921/4885RIMKLA 3165/4885 |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | CTSL, CPA4, ACE2 | FOLH1 308/4885NAALAD2 191/4885RIMKLA 2031/4885 |
| US-20220162261-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | FOLH1 2497/4885NAALAD2 1441/4885RIMKLA 4036/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | FOLH1 1381/4885NAALAD2 87/4885RIMKLA 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.